跳至主要内容
临床试验/CTIS2024-514413-36-00
CTIS2024-514413-36-00进行中(未招募)1 期

BS-03

Bluesky Immunotherapies GmbH0 个研究点目标入组 12 人开始时间: 2024年7月12日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

年龄范围
18 至 64(—)
性别
All

入选标准

  • 未提供

排除标准

  • 未提供

研究者

相似试验

招募中
1 期
A Study of NB003 in Patients With Advanced Malignancies
CTIS2022-502401-15-00ingbo Newbay Technology Development Co. Ltd.290
进行中(未招募)
1 期
Pharmacokinetic comparison of efanesoctocog alfa vs other EHL-rFVIII products in participants with severe haemophilia AHaemophilia AMedDRA version: 20.0Level: LLTClassification code: 10018937Term: Haemophilia A Class: 10010331
CTIS2023-505801-17-00Swedish Orphan Biovitrum AB (publ)24
进行中(未招募)
1 期
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)Diffuse large B-cell lymphoma (DLBCL), Grade 3B follicular lymphoma, High grade B-cell lymphoma (HGBL), Epstein-Barr virus-positive DLBCLMedDRA version: 21.0Level: PTClassification code: 10012818Term: Diffuse large B-cell lymphoma Class: 100000004864
CTIS2023-507497-40-00F. Hoffmann-La Roche AG50
进行中(未招募)
1 期
Assessment of narrowing of blood vessels after single application of two clascoterone formulations (cream and solution) onto the skin in comparison to three marketed topical corticosteroidsTest of vasocontriction properties for classification of topical steroid potencyMedDRA version: 20.0Level: LLTClassification code: 10047140Term: Vasoconstriction peripheral Class: 10047065
CTIS2023-507241-28-00Cassiopea S.p.A.33
进行中(未招募)
1 期
MK-1403 Single Dose Formulation PK StudyMedDRA version: 20.0Level: LLTClassification code: 10003601Term: Atherosclerosis Class: 10047065Atherosclerosis
CTIS2023-507984-20-00Merck Sharp & Dohme LLC16